Wundrsight Raises $400K In Seed Round Led By Inflection Point Ventures

Digital therapeutics startup Wundrsight secured USD 400 thousand in a seed round led by Inflection Point Ventures. Social Alpha also joined the round, along with other angel investors. 

This investment will enable Wundrsight to expand its network of hospital and clinic partnerships across India and accelerate the development of its innovative VR-based mental health solutions.

Vikram Ramasubramanian, Partner, Inflection Point Ventures said, “The mental health crisis is more alarming than ever; solving it with just traditional methods is often limited to accessibility, personalised treatment, and engagement. Many people start therapy but frequently drop off due to ineffective retention and engagement strategies. Wundrsight is at the forefront of addressing these issues by bringing in digital therapeutic and mixed reality technology like Virtual Reality to create personalized, immersive, and effective mental health care experiences.”

With a focus on evidence-based practices, they're pioneering VR therapy in India, backed by Central Drugs Standard Control Organisation (CDSCO) registration, International Organisation for Standardisation (ISO) certifications, and Clinical Trials Registry – India (CTRI) registered clinical trials, as per the statement.

Currently operating in three metro cities, they have secured contracts with over five hospitals, with additional partnerships with leading private and government hospitals underway, the company said. Offering more than six VR therapy products, the startup has successfully treated over 1000 patients across various mental health conditions, including Substance Use Disorders, Obsessive Compulsive Disorder (OCD), Anxiety, Phobia, and Autism, with clinician-administered therapies.

“We are at a pivotal moment in mental health care, especially now as innovative software-based medical devices are getting regulatory approvals for prescriptions,” said Raunak Swarnkar, Co-Founder & CEO, Wundrsight. 

He added, “Our VR-based solutions not only reduce the need for medication but also enhance clinician efficiency, allowing for safe, standardized and effective treatments. This funding will help us expand our reach and impact in India and APAC. We look forward to entering the US market next where VR therapy has received CPT codes for reimbursement from insurance providers.”